New studies released earlier this month raise troubling questions about the effectiveness of two prescript medications used to control cholesterol. The generic products Ezetimibe--marketed under the registered trademark Zetia--and Ezetimibe/Simvastatin--marketed under the registered trademark Vytorin--apparently aren't effective, as represented by their manufacturers.
Disclosure: the author of this blog routinely handles consumer class actions and may become involved in this litigation in the future.
Consumers are lining up in various states to pursue claims for reimbursements and refunds for money spent on these drugs. According to a complaint filed in U.S. District Court of Kansas, the drugs are alleged to increase the formation of fatty plaques, which raises the risk of heart attack.
It's going to be interesting to see how this plays out.
David F. Sugerman
Paul & Sugerman, PC